Introduction
Epileptic spasms (ES) is an often devastating form of epilepsy that usually begins in the first year of life and typically accompanies one of many structural, genetic, or metabolic disorders [1] . Clusters of brief, and often subtle spasms typically occur in association with a highly chaotic EEG background pattern known as hypsarrhythmia [2] . First-line therapies including vigabatrin [3] , adrenocorticotropic hormone (ACTH) [4] , and prednisolone [5] exhibit robust efficacy but unfavorable risk profiles. Foremost, ACTH and prednisolone pose risk of serious bacterial infection. At least with long-term use, vigabatrin poses a threat to peripheral vision [6] , and even short courses may present a risk of movement disorders and other phenomena associated with MRI brain signal changes [7] . As such, there is tremendous demand for safe and effective therapies in the treatment of ES, and the ketogenic diet has been touted as a candidate to help fill this void. Some have argued that the diet is a reasonable option for first-line therapy [8, 9] , a view supported by a large series of openlabel contemporary reports that all suggest substantial efficacy (see Table 1 ), including many patients with quite refractory ES [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . However, these studies all lack placebo controls and blinded outcome ascertainment, and none have established rapid resolution of hypsarrhythmia with overnight video-EEG. Although several prior studies have utilized EEG to bolster the impression of efficacy, EEG has generally been implemented in an inconsistent fashion, often without video, and with short-duration studies performed months after ketogenic diet initiation. With regard to [25] [26] [27] . As our subjective impression of ketogenic diet therapy for ES has been less favorable than described in these recent reports, and because it contrasts with generally favorable outcomes of ketogenic diet therapy for other forms of refractory epilepsy (e.g. Lennox-Gastaut syndrome), we sought to systematically describe our center's experience with the ketogenic diet for the treatment of ES.
Methods

Standard protocol approvals
This use of human subjects and the analyses presented here were approved by the Institutional Review Board at UCLA. The requirement for written informed consent was waived.
Patients
We retrospectively identified patients using electronic health records and specifically included all patients with video-EEG confirmed ES who were evaluated at the Mattel Children's Hospital UCLA and treated with the ketogenic diet between April, 2010 and June, 2014. There were no exclusion criteria.
Primary and secondary outcome measures
Our primary outcome of interest was the percentage of patients with complete response to the ketogenic diet, with video-EEG confirmed resolution of both spasms and hypsarrhythmia. Our secondary outcomes of interest were change in median daily seizure (spasm) frequency, and the 50% and 90% responder rates after 1, 3, 6, and 12 months of ketogenic diet exposure.
Data ascertainment
For each patient, clinical and demographic data including etiology, treatment history, and lead-time to diet initiation were tabulated, as well as spasm frequency and video-EEG data at baseline and at 1, 3, 6, and 12 months following initiation of the diet. Tolerability data, including early (<2 weeks following diet initiation) and late (>2 weeks) treatment emergent adverse events (TEAEs) during therapy were similarly recorded. To ascertain diet exposure and ''dose'', we recorded two dosage measures at each visit: (1) the mass ratio of dietary fat to non-fat (protein + carbohydrate) sources, and (2) the percentage of dietary calories derived from fat. This allowed tabulation of cumulative and peak diet ratio and percentage of calories derived from fat. Lastly, peak serum betahydroxybutyrate level achieved during diet exposure was similarly recorded for each patient.
UCLA ketogenic diet protocol for infants
We follow a standardized procedure in which the ketogenic diet is commenced on an inpatient basis. Briefly, the initial goal dietary ratio (by mass) of fat to carbohydrate and protein is 3:1. Using Ketocal 1 ketogenic formula (Nutricia North America, Gaithersburg, MD, USA) mixed with either breastmilk or formula, we typically administer 1/3 strength formula (33% by volume) on day 1, 2/3 strength on day 2, and full strength on day 3. The speed of titration is occasionally slower in the event of hypoglycemia, diarrhea, or other intolerance. Further titration of the ratio (rarely >4:1) or the use of additional medium chain triglycerides is frequently employed. We specifically do not fast patients at diet initiation. According to our clinical protocol, we require overnight video-EEG confirmation of clinical response (parent-reported resolution of seizures) for children with ES. These EEG studies are typically 16-22 h in duration and always encompass multiple sleep-wake cycles, and importantly, the epoch immediately following first morning awakening when spasms are most frequent.
Statistical methods
Variables with nonparametric distributions were reported as median and interquartile range (IQR). Paired comparisons of medians were accomplished using the Wilcoxon Signed-Rank test (WSR), with STATA software (version 11, Statacorp, College Station, TX, USA). Adjustment for multiple comparisons was not undertaken.
Results
Study population
During the study period, 154 patients with video-EEG confirmed ES were evaluated at our center and we identified 22 (14.3%) patients who were treated with the ketogenic diet. All patients exhibited at least daily clusters of epileptic spasms as the dominant seizure-type, though other co-morbid seizures were common. No patient met criteria for Lennox-Gastaut syndrome at diet initiation. Characteristics of the study population are summarized in Table 2 . As expected, this cohort represented a highly refractory subset of children with ES, with exceptionally long duration of ES prior to ketogenic diet initiation, and multiple prior treatment failures. The order in which treatments were undertaken was not strictly protocalized, though the ketogenic diet was never implemented first-line and typically followed the failure of multiple first-and second-line therapies. Regarding etiology, 12 patients were classified as structural, four as genetic, two as structural-genetic, and four as unknown etiology. All four patients without an identified cause of ES exhibited substantial developmental delay prior to onset of ES. Although most patients exhibited hypsarrhythmia at some point prior to diet initiation, only seven (31.8%) demonstrated hypsarrhythmia at the time of diet initiation. Among those without continued hypsarrhythmia at diet initiation, most pre-treatment EEG studies demonstrated a large burden of interictal epileptiform discharges and slowing.
None of the EEGs exhibited consistently high voltage (>200 mV), and none exhibited a normal interictal background.
Ketogenic diet exposure
The median duration of diet therapy was 9.1 months (IQR 6.6-22.2). The median peak ratio of dietary fat to non-fat (carbohydrate + protein) was 3.5 (IQR 3.0-4.0) and the median cumulative weighted average ratio during diet therapy was 3.0 (IQR 2.5-3.6). Similarly, the median peak proportion of dietary calories derived from fat was 0.89 (IQR 0.87-0.90) and the median cumulative weighted average proportion was 0.87 (IQR 0.85-0.89). Median peak serum betahydroxybutyrate concentration was 5.4 mmol/L (IQR 3.9-6.7).
Seizure-related outcomes
Median baseline parent-reported seizure frequency was 27.5 spasms/day (IQR 15.0-45.0). Although seizure-frequency at 1 month (20.0, IQR 12.0-30.0) was significantly lower than baseline (p = 0.042, WSR), this reduction was not sustained at 3, 6, and 12 months for those children who remained on the diet (Fig. 1) . Similarly, the percentage of patients with at least a 50% reduction in seizure frequency was 31.8, 30.0, 29.4, and 20.0, at 1, 3, 6, and 12 months, respectively. The percentage of patients with at least a 90% reduction in seizure frequency was 0, 0, 11.8, and 0, at 1, 3, 6, and 12 months, respectively.
Two patients exhibited a complete and sustained response during ketogenic diet therapy with video-EEG-verified freedom from both spasms and hypsarrhythmia. Both patients had remote hypsarrhythmia, but neither patient exhibited hypsarrhythmia just prior to diet initiation. Of these two children, one responded two days after beginning vigabatrin therapy, which followed 3.5 months of diet exposure. At most recent follow-up, the patient remains seizure-free 2 months after stopping diet therapy, with continued vigabatrin treatment. The other responder exhibited spasms remission 21 months after diet initiation, on the same day that a vagal nerve stimulator was placed. This child also remains seizure-free at most recent follow-up, 8 months after discontinuation of the ketogenic diet. One additional patient with bifrontal cortical dysplasia and remote hypsarrhythmia briefly exhibited seizure freedom after 5.5 months on the diet, but relapsed at 6.5 months -and was thus a responder at 6 months but not at 12 months. This patient remains on the diet at most recent follow-up based on ''partial'' response. At most recent follow-up, 6 (27%) patients remain on the diet with the impression of subjectivethough incomplete -efficacy for treatment of spasms, or efficacy in the treatment of other comorbid seizure-types.
Tolerability outcomes
TEAEs potentially attributable to the ketogenic diet are summarized in Table 3 . Among TEAEs occurring within the first two weeks of diet therapy, lethargy, hypoglycemia, acidosis, nausea/vomiting, and constipation were observed in more than 10% of patients. As expected, hypoglycemia (54.5%) and acidosis (40.9%) were frequently encountered, but easily managed with diet adjustments. Similarly, late TEAEs occurring more than two weeks after diet initiation and affecting more than 10% of patients included lethargy (18.2%), acidosis (50.0%), nausea/vomiting (36.4%), diarrhea (18.2%), constipation (68.2%), hypercholesterolemia (31.8%), hypertriglyceridemia (40.9), hypocarnitinemia (63.6%), and hypercalciuria (63.6%). On retrospective review, it does not appear that any patient discontinued ketogenic diet therapy on the basis of any individual TEAE. These frequent and usually mild TEAEs were routinely addressed with diet adjustments or other routine countermeasures. As an example, urinary alkalization was routinely undertaken for hypercalciuria and we did not observe any cases of nephrolithiasis in this cohort. Furthermore, many TEAEs were attributed at least in part to other treatments rendered during diet therapy (e.g. acidosis with topiramate therapy), but nevertheless tabulated in this report.
Discussion
Despite adequate trials of the ketogenic diet, we have observed rather disappointing response in our cohort of patients with highly refractory ES. Foremost, we did not encounter a single child with complete response for which diet therapy was a likely catalyst; of the two responders, alternative therapies were almost certainly responsible for resolution of spasms. It is not altogether surprising that this cohort would have a poor response to any effective therapy based on the reported etiologies [28] , potential epileptogenesis during exceptionally long delays between spasms-onset and diet initiation [29] , and multiple pre-diet treatment failures. Nevertheless, the ketogenic diet appears to confer some benefit in this population, as many patients continue therapy in the absence of a complete response. In addition, we only assessed epilepsy outcomes and, because of the limitations our retrospective design, we could not rigorously explore potential cognitive or behavioral outcomes which often accompany the successful treatment of ES. Table 2 Characteristics of the study population (n = 22).
Demographics
Female sex, n (%) 11 (50.0) Age at spasms onset, months Had we conducted prospective, standardizied/quantitative -and ideally blinded -neurocognitive testing, it would have greatly strengthened this analysis, and we might have been able to demonstrate that the ketogenic diet confers cognitive benefit despite a lack of improvement in seizure burden. Indeed, several patients in this series continued ketogenic diet therapy with the qualitative and perhaps biased impression of cognitive improvement.
Like all past studies of the ketogenic diet for treatment of ES, this study is plagued by several major methodological limitations, among them a retrospective design, and lack of randomization, experimental controls, and blinded outcome assessment -all critical factors for any study that seeks to evaluate the efficacy of a treatment. Even in assessing ''partial response'' we were not sufficiently powered to detect small reductions in spasmfrequency. Nonetheless, our lack of response is a significant departure from the aforementioned reports of success with the ketogenic diet in refractory populations.
Aside from the highly refractory character of our study cohort, we suspected that our response rate might be low because we employ appropriately strict outcome assessment; as spasms are often quite subtle [30, 31] -especially with partial response after treatment -we routinely perform overnight video-EEG to verify parental report of spasms resolution and to ensure concomitant resolution of hypsarrhythmia. However, although we continue to endorse this procedure, we did not encounter any patient in this series with continued spasms on EEG despite parental report of resolution. Similarly, we did not encounter persistent hypsarrhythmia in any patient with EEG-proven spasms resolution, as had been observed in a prior case series [5] .
Our response rate might have been higher if our patients had been treated for longer durations. The ketogenic diet does not appear to yield quick resolution of spasms and hypsarrhythmia, especially in contrast to hormonal therapies and vigabatrin. In a retrospective study contrasting the ketogenic diet and ACTH as first-line therapies, Kossoff and colleagues showed a trend toward ACTH superiority with respect to spasm-freedom at 1-month in an underpowered comparison, and rather compelling ACTH superiority with respect to hypsarrhythmia-resolution at 1-month among the subset of patients with EEG follow-up [14] . This same theme with a modest rate of spasms-freedom (18% at 3-months) and slow hypsarrhythmia resolution was recapitulated in a very large and contemporary case series from the same group [17] , which included patients with refractory ES. Still, the ultimate developmental cost of slow electrographic resolution is unknown and is likely negligible in patients with severe underlying etiologies of ES and lack of developmental regression at the onset of ES. It should also be noted that there is no consensus on the ideal duration of follow-up EEG to confirm hypsarrhythmia resolution, and the utility of this practice is diminished by poor inter-rater reliability in the identification of hypsarrhythmia [32] . Furthermore, there is disagreement as to what exactly constitutes ''resolution'' of hypsarrhythmia, and whether or not this is an adequate electrographic outcome measure.
Lastly, in assessing the efficacy of any therapy that requires a long treatment course, we must consider the natural history. Based on the observations of Jeavons [33] and Hrachovy [34] , the rate of spontaneous spasms-resolution is fairly linear and approximately 25% per year. Only 30% of children were spasms-free at 12-months in the report of Hong and colleagues [17] . Such comparison is admittedly haphazard but underscores the need to disentangle slow response from spontaneous response.
To be clear, our data do not argue against the use of the ketogenic diet in all patients with ES, and they cannot be used to guide the management of treatment-naïve patients. Moreover, there are certainly patients (e.g. GLUT1 transporter deficiency) for whom the ketogenic diet should be administered first-line [35] . We have only shown that the ketogenic diet is reasonably welltolerated and of limited efficacy among our highly-refractory cohort. To reconcile our unsatisfactory experience with the large body of methodologically-limited data supporting the ketogenic diet, a randomized and blinded study, with gold-standard clinical and electrographic outcome assessment, would be of great value. Until then, we will continue to offer the ketogenic diet to patients who fail first-line therapies, though with appropriately guarded expectations for success.
